KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Receivables (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Change in Receivables readings, the most recent being $15.5 million for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 112.36% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.8 million, a 62.16% increase, with the full-year FY2025 number at $36.8 million, up 62.16% from a year prior.
  • Change in Receivables hit $15.5 million in Q4 2025 for Biocryst Pharmaceuticals, up from $17000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $18.7 million in Q2 2021 to a low of -$3.8 million in Q3 2023.
  • Median Change in Receivables over the past 5 years was $4.6 million (2022), compared with a mean of $5.4 million.
  • Biggest five-year swings in Change in Receivables: skyrocketed 2600.38% in 2022 and later crashed 358.96% in 2023.
  • Biocryst Pharmaceuticals' Change in Receivables stood at $3.2 million in 2021, then skyrocketed by 136.04% to $7.6 million in 2022, then crashed by 61.14% to $3.0 million in 2023, then surged by 145.66% to $7.3 million in 2024, then surged by 112.36% to $15.5 million in 2025.
  • The last three reported values for Change in Receivables were $15.5 million (Q4 2025), $17000.0 (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.